Navigation Links
Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
Date:11/20/2008

STAMFORD, Conn, Nov. 20 /PRNewswire/ -- Purdue Pharma L.P. and Mundipharma International Corporation Limited, today announced that they have entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity's discovery and early clinical programs in the areas of oncology and neuropathic pain.

The alliance will focus on supporting Infinity's pipeline of novel, small molecule oncology drug candidates, including IPI-926, a potent inhibitor of the Hedgehog pathway, which is being evaluated in a Phase 1 clinical study in patients with advanced solid tumors. IPI-926 has demonstrated significant anti-tumor activity in a number of preclinical models. Infinity will direct and lead oncology discovery and development efforts on a worldwide basis. Under the terms of the agreements, Infinity will retain United States commercialization rights for all oncology products developed under these programs and will pay Mundipharma a royalty on U.S. sales. Mundipharma has the right to commercialize these products outside of the United States, and will pay a royalty to Infinity on sales outside of the United States.

Under a separate agreement, Purdue's associated company, Purdue Pharmaceutical Products L.P., and Mundipharma will have the worldwide rights to assume development of Infinity's fatty acid amide hydrolase (FAAH) program, an experimental target for the treatment of neuropathic pain, at the conclusion of Phase 1 clinical studies. Infinity's FAAH inhibitor program is in lead optimization and the company expects to select a clinical candidate by early 2009. Purdue and Mundipharma will fund all research and development costs of the program through regulatory approval, and will pay a royalty to Infinity on global net sales of any products commercialized.

"Purdue U.S., Purdue Canada, and Mundipharma companies in Europe and Asia have been expanding their therapeutic scope significantly in recent years," said Jim Dolan, Senior Vice President of Licensing and Business Development for Purdue. "Mundipharma's presence in oncology outside of the U.S. is now well-established, and we expect that the broad alliance with Infinity will give us the opportunity to bring to market a number of innovative, best-in-class treatments for cancer patients. In addition, this alliance will also build upon our core franchise in pain on a global basis, with FAAH, a potentially innovative new product for neuropathic pain."

"Infinity's mission is to discover, develop, and deliver to patients important medicines for the treatment of cancer," said Steve H. Holtzman, chair and chief executive officer of Infinity. "This alliance with Purdue and Mundipharma provides Infinity with the financial resources and independence to continue our productive discovery efforts, to expand our clinical development capabilities, and to build our own organization to commercialize our products in the United States. In a nutshell, we have the opportunity to realize all aspects of our mission in a manner that we believe will create meaningful treatments for patients and meaningful value for our shareholders."

The Purdue/Mundipharma/Napp independent associated companies are privately owned companies and joint ventures covering the world's pharmaceutical markets. The companies have particular expertise in drug delivery systems and these are applied to a range of analgesics, respiratory treatments, and cardiovascular drugs. The companies also have a growing presence in the oncology market, and products in the areas of attention deficit hyperactivity disorder, antiseptics and laxatives.


'/>"/>
SOURCE Purdue Pharma L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NIH grant to strengthen IU and Purdue program to educate physician-scientists
2. Purdue lab works to improve conditions at indoor swimming pools
3. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
4. Purdue researchers develop technology to detect cancer by scanning surface veins
5. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
6. Parkland Health & Hospital System Rolls Out Innovations PharmASSIST Technology Platform Across Nine Pharmacy Sites
7. NCPA Encourages Member Pharmacists to Consider Refraining From Selling Tobacco Products
8. Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
9. Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery
10. Kmart Pharmacy Celebrates GoldK Day for Seniors
11. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... Thailand (PRWEB) , ... August 19, 2017 , ... ... Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness ... in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
Breaking Medicine Technology: